GT Biopharma, Inc. (GTBP) Stock

Healthcare · Biotechnology · Member of Other US Stocks

GT Biopharma, Inc. (GTBP) closed at USD 6.21 on 2026-10-14, a change of +806.6 % over the past year, with a market capitalization of USD 15.17M.

GT Biopharma, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

GT Biopharma, Inc. key figures

Previous close

USD 6.21 (2026-10-14)

1-year change

+806.6 %

Market cap

USD 15.17M

Enterprise value

USD 8.32M

P/E ratio (trailing)

-0.04

P/E ratio (forward)

-0.68

EPS (trailing)

-171.23

EPS (forward)

-10.80

PEG ratio

1.05

Price to book

3.69

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.24

Employees

1

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About GT Biopharma, Inc.

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for GT Biopharma, Inc. and compare it with other stocks.